Macromoltek Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 13
Employees
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 8

Macromoltek General Information

Description

Developer of molecular modeling software designed to analyze potential antibody drug candidates. The company's platform uses its data algorithms to optimize the selection process, solves antibody structures computationally, and offers an online workspace, enabling researchers to make new discoveries by keeping the focus on their science.

Contact Information

Website
www.macromoltek.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2500 West William Cannon Drive
  • Suite 204
  • Austin, TX 78745
  • United States
+1 (512) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Macromoltek Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 01-Jan-2020 00000 Completed Generating Revenue
7. Later Stage VC 00000 00000 Completed Generating Revenue
6. Accelerator/Incubator 19-Mar-2018 00000 00000 00.000 Completed Generating Revenue
5. Seed Round 01-Jan-2018 Completed Generating Revenue
4. Grant 20-Aug-2016 00000 Completed Startup
3. Accelerator/Incubator 01-Mar-2015 Completed Startup
2. Grant 01-Jan-2015 $150K Completed Startup
1. Accelerator/Incubator 10-Dec-2014 Completed Startup
To view Macromoltek’s complete valuation and funding history, request access »

Macromoltek Patents

  • 2

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Macromoltek Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210246203-A1 Compositions and methods for treating progressive neurodegenerative diseases Pending 21-Aug-2018 000000000
US-20140100834-A1 Computational methods for analysis and molecular design of antibodies, antibody humanization, and epitope mapping coupled to a user-interactive web browser with embedded three- dimensional rendering Abandoned 04-Oct-2012 000000000

Macromoltek Executive Team (2)

Name Title Board Seat Contact Info
Monica Berrondo Ph.D Co-Founder & Chief Executive Officer
Susana Kaufmann Co-Founder & Chief Technology Officer
To view Macromoltek’s complete executive team members history, request access »

Macromoltek Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Macromoltek Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
DCVC Venture Capital Minority 000 0000 000000 0
Y Combinator Accelerator/Incubator Minority 000 0000 000000 0
Ataria Ventures Venture Capital Minority 000 0000 000000 0
DCVC Bio Venture Capital Minority 000 0000 000000 0
Neotribe Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial